Skip to main content
PMC home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 2004 Oct;58(10):822–825. doi: 10.1136/jech.2003.008664

To control and beyond: moving towards eliminating the global tuberculosis threat

T Brewer 1, S Heymann 1
PMCID: PMC1763333  PMID: 15365106

Abstract

For 10 years the World Health Organisation has had a single answer to the deadly threat of tuberculosis (TB)—provide treatment to smear positive patients and watch them take it. In contrast with confident statements about how global TB would be brought under control when directly observed therapy, short course (DOTS) was introduced, TB continues to rise worldwide. The introduction of selected multiple drug resistant TB treatment programmes, "DOTS-Plus", although important, also focuses on therapy for active TB. HIV endemic countries in particular have experienced tremendous increases in TB despite having DOTS programmes. A critical review of recent epidemiological data and computer models shows that the present international strategy of concentrating on providing treatment for smear positive TB, DOTS and DOTS-Plus, is likely to have only a modest impact on population based TB control. Effective global TB control will require strategies that go beyond relying on treatment of people with active disease.

Full Text

The Full Text of this article is available as a PDF (103.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allos B. M., Genshelmer K. F., Bloch A. B., Parrotte D., Horan J. M., Lewis V., Schaffner W. Management of an outbreak of tuberculosis in a small community. Ann Intern Med. 1996 Jul 15;125(2):114–117. doi: 10.7326/0003-4819-125-2-199607150-00007. [DOI] [PubMed] [Google Scholar]
  2. Behr M. A., Warren S. A., Salamon H., Hopewell P. C., Ponce de Leon A., Daley C. L., Small P. M. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999 Feb 6;353(9151):444–449. doi: 10.1016/s0140-6736(98)03406-0. [DOI] [PubMed] [Google Scholar]
  3. Bishai W. R., Graham N. M., Harrington S., Pope D. S., Hooper N., Astemborski J., Sheely L., Vlahov D., Glass G. E., Chaisson R. E. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA. 1998 Nov 18;280(19):1679–1684. doi: 10.1001/jama.280.19.1679. [DOI] [PubMed] [Google Scholar]
  4. Bleed D., Dye C., Raviglione M. C. Dynamics and control of the global tuberculosis epidemic. Curr Opin Pulm Med. 2000 May;6(3):174–179. doi: 10.1097/00063198-200005000-00002. [DOI] [PubMed] [Google Scholar]
  5. Brewer T. F., Heymann S. J., Colditz G. A., Wilson M. E., Auerbach K., Kane D., Fineberg H. V. Evaluation of tuberculosis control policies using computer simulation. JAMA. 1996 Dec 18;276(23):1898–1903. [PubMed] [Google Scholar]
  6. Brudney K., Dobkin J. A tale of two cities: tuberculosis control in Nicaragua and New York City. Semin Respir Infect. 1991 Dec;6(4):261–272. [PubMed] [Google Scholar]
  7. Cantwell M. F., Binkin N. J. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. Tuber Lung Dis. 1996 Jun;77(3):220–225. doi: 10.1016/s0962-8479(96)90004-0. [DOI] [PubMed] [Google Scholar]
  8. Churchyard G. J., Kleinschmidt I., Corbett E. L., Mulder D., De Cock K. M. Mycobacterial disease in South African gold miners in the era of HIV infection. Int J Tuberc Lung Dis. 1999 Sep;3(9):791–798. [PubMed] [Google Scholar]
  9. Cohn D. L., Catlin B. J., Peterson K. L., Judson F. N., Sbarbaro J. A. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med. 1990 Mar 15;112(6):407–415. doi: 10.7326/0003-4819-76-3-112-6-407. [DOI] [PubMed] [Google Scholar]
  10. Comstock G. W., Ferebee S. H., Hammes L. M. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967 Jun;95(6):935–943. doi: 10.1164/arrd.1967.95.6.935. [DOI] [PubMed] [Google Scholar]
  11. De Cock K. M., Chaisson R. E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis. 1999 Jun;3(6):457–465. [PubMed] [Google Scholar]
  12. Dye C., Garnett G. P., Sleeman K., Williams B. G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet. 1998 Dec 12;352(9144):1886–1891. doi: 10.1016/s0140-6736(98)03199-7. [DOI] [PubMed] [Google Scholar]
  13. Dye C., Scheele S., Dolin P., Pathania V., Raviglione M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999 Aug 18;282(7):677–686. doi: 10.1001/jama.282.7.677. [DOI] [PubMed] [Google Scholar]
  14. Dye C. Tuberculosis 2000-2010: control, but not elimination. Int J Tuberc Lung Dis. 2000 Dec;4(12 Suppl 2):S146–S152. [PubMed] [Google Scholar]
  15. Enarson D. A. Controlling tuberculosis--is it really feasible? Tuber Lung Dis. 2000;80(2):57–59. doi: 10.1054/tuld.2000.0238. [DOI] [PubMed] [Google Scholar]
  16. Espinal M. A., Kim S. J., Suarez P. G., Kam K. M., Khomenko A. G., Migliori G. B., Baéz J., Kochi A., Dye C., Raviglione M. C. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000 May 17;283(19):2537–2545. doi: 10.1001/jama.283.19.2537. [DOI] [PubMed] [Google Scholar]
  17. Espinal M. A., Laszlo A., Simonsen L., Boulahbal F., Kim S. J., Reniero A., Hoffner S., Rieder H. L., Binkin N., Dye C. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001 Apr 26;344(17):1294–1303. doi: 10.1056/NEJM200104263441706. [DOI] [PubMed] [Google Scholar]
  18. Frieden T. R., Fujiwara P. I., Washko R. M., Hamburg M. A. Tuberculosis in New York City--turning the tide. N Engl J Med. 1995 Jul 27;333(4):229–233. doi: 10.1056/NEJM199507273330406. [DOI] [PubMed] [Google Scholar]
  19. Frieden T. R., Sherman L. F., Maw K. L., Fujiwara P. I., Crawford J. T., Nivin B., Sharp V., Hewlett D., Jr, Brudney K., Alland D. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA. 1996 Oct 16;276(15):1229–1235. [PubMed] [Google Scholar]
  20. Grosskurth H., Mosha F., Todd J., Mwijarubi E., Klokke A., Senkoro K., Mayaud P., Changalucha J., Nicoll A., ka-Gina G. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995 Aug 26;346(8974):530–536. doi: 10.1016/s0140-6736(95)91380-7. [DOI] [PubMed] [Google Scholar]
  21. Gupta R., Raviglione M. C., Espinal M. A. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? Int J Tuberc Lung Dis. 2001 Dec;5(12):1078–1079. [PubMed] [Google Scholar]
  22. Henderson D. A. The challenge of eradication: lessons from past eradication campaigns. Int J Tuberc Lung Dis. 1998 Sep;2(9 Suppl 1):S4–S8. [PubMed] [Google Scholar]
  23. Heymann S. J. Modelling the efficacy of prophylactic and curative therapies for preventing the spread of tuberculosis in Africa. Trans R Soc Trop Med Hyg. 1993 Jul-Aug;87(4):406–411. doi: 10.1016/0035-9203(93)90014-h. [DOI] [PubMed] [Google Scholar]
  24. Isaac-Renton J. L., Puselja B. B., Allen E. A., Grzybowski S., Black W. A. Microscopic evaluation of sputum specimens submitted for Mycobacterium tuberculosis culture. Am J Clin Pathol. 1985 Sep;84(3):361–363. doi: 10.1093/ajcp/84.3.361. [DOI] [PubMed] [Google Scholar]
  25. Kenyon T. A., Mwasekaga M. J., Huebner R., Rumisha D., Binkin N., Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis. 1999 Jan;3(1):4–11. [PubMed] [Google Scholar]
  26. Kim S. J., Bai G. H., Hong Y. P. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis. 1997 Aug;1(4):302–308. [PubMed] [Google Scholar]
  27. Kim T. C., Blackman R. S., Heatwole K. M., Kim T., Rochester D. F. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Prevalence and significance of negative smears pretreatment and positive smears post-treatment. Am Rev Respir Dis. 1984 Feb;129(2):264–268. [PubMed] [Google Scholar]
  28. Kimerling M. E. The Russian equation: an evolving paradigm in tuberculosis control. Int J Tuberc Lung Dis. 2000 Dec;4(12 Suppl 2):S160–S167. [PubMed] [Google Scholar]
  29. Miller B., Castro K. G. Sharpen available tools for tuberculosis control, but new tools needed for elimination. JAMA. 1996 Dec 18;276(23):1916–1917. [PubMed] [Google Scholar]
  30. Mitchison D. A. The origins of DOT. Int J Tuberc Lung Dis. 1998 Oct;2(10):863–865. [PubMed] [Google Scholar]
  31. Raviglione M. C., Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet. 2002 Mar 2;359(9308):775–780. doi: 10.1016/s0140-6736(02)07880-7. [DOI] [PubMed] [Google Scholar]
  32. Raviglione M. C., Snider D. E., Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA. 1995 Jan 18;273(3):220–226. [PubMed] [Google Scholar]
  33. Reichman L. B. Tuberculosis elimination--what's to stop us? Int J Tuberc Lung Dis. 1997 Feb;1(1):3–11. [PubMed] [Google Scholar]
  34. Selwyn P. A., Sckell B. M., Alcabes P., Friedland G. H., Klein R. S., Schoenbaum E. E. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992 Jul 22;268(4):504–509. [PubMed] [Google Scholar]
  35. Suárez P. G., Watt C. J., Alarcón E., Portocarrero J., Zavala D., Canales R., Luelmo F., Espinal M. A., Dye C. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis. 2001 Jul 18;184(4):473–478. doi: 10.1086/322777. [DOI] [PubMed] [Google Scholar]
  36. Wenger J. D. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J. 1998 Sep;17(9 Suppl):S132–S136. doi: 10.1097/00006454-199809001-00008. [DOI] [PubMed] [Google Scholar]
  37. Whalen C. C., Johnson J. L., Okwera A., Hom D. L., Huebner R., Mugyenyi P., Mugerwa R. D., Ellner J. J. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997 Sep 18;337(12):801–808. doi: 10.1056/NEJM199709183371201. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES